Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TENAX THERAPEUTICS, INC.

(TENX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
2.14(c) 2.08(c) 2.03(c) 2.03(c) 1.92(c) Last
125 826 39 828 49 867 61 338 110 022 Volume
+2.88% -2.80% -2.40% 0.00% -5.42% Change
More quotes
Financials (USD)
Sales 2021 - - -
Net income 2021 -33,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,20x
Yield 2021 -
Sales 2022 25,0 M - -
Net income 2022 3,65 M - -
Net Debt 2022 - - -
P/E ratio 2022 -21,3x
Yield 2022 -
Capitalization 48,4 M 48,4 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 1,94x
Nbr of Employees -
Free-Float 67,0%
More Financials
Company
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of... 
More about the company
All news about TENAX THERAPEUTICS, INC.
06/11TENAX THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holders ..
AQ
06/10TENAX THERAPEUTICS  : Set to Join Russell Microcap® Index
BU
05/17TENAX THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/17TENAX THERAPEUTICS  : Earnings Flash (TENX) TENAX THERAPEUTICS Posts Q1 Loss $-1..
MT
05/17TENAX THERAPEUTICS  : Reports First Quarter 2021 Results and Provides Business U..
BU
04/27Medical supplies flow into India as COVID-19 deaths near 200,000
RE
04/21TENAX THERAPEUTICS  : Indian COVID-19 patients die as ventilators run out of oxy..
RE
04/20Oxygen shares, real and imaginary, rally as India battles virus surge
RE
04/09TENAX THERAPEUTICS'  : Levosimendan Drug Candidate Shows Positive Results in Hyp..
MT
04/09MIDDAY REPORT : Wall Street Firmer Midday Amid Producer Prices Spike
MT
04/09TENAX ANNOUNCES PUBLICATION TITLED & : Results of the Randomized Placebo-Control..
BU
04/07TENAX THERAPEUTICS  : Directors Blanck, Pepin, and Rallis Won't Seek Re-Election..
MT
04/07TENAX THERAPEUTICS  : Announces Continuation of Board Refreshment Program as Thr..
BU
03/31TENAX THERAPEUTICS  : Posts Lower Fiscal 2020 Net Loss of $1.33 a Share
MT
03/31TENAX THERAPEUTICS  : Reports Fiscal Year 2020 Results and Provides Business Upd..
BU
More news
News in other languages on TENAX THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on TENAX THERAPEUTICS, INC.
More recommendations
Chart TENAX THERAPEUTICS, INC.
Duration : Period :
Tenax Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TENAX THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 4,75 $
Last Close Price 1,92 $
Spread / Highest target 160%
Spread / Average Target 147%
Spread / Lowest Target 134%
EPS Revisions
Managers and Directors
NameTitle
Anthony A. DiTonno Chief Executive Officer & Director
Michael B. Jebsen President & Chief Financial Officer
Gerald T. Proehl Chairman
Stuart Rich Director & Chief Medical Officer
Doug Randall Executive VP-Commercial & Business Operations
Sector and Competitors
1st jan.Capitalization (M$)
TENAX THERAPEUTICS, INC.3.23%48
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367